Lifecore Biomedical, Inc. (LFCR)
(Delayed Data from NSDQ)
$6.00 USD
+0.29 (5.08%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $5.99 -0.01 (-0.17%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.00 USD
+0.29 (5.08%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $5.99 -0.01 (-0.17%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Zacks News
Lifecore (LFCR) Down 30% on Ending Strategic Review With No Deal
by Zacks Equity Research
Lifecore (LFCR) ends a year-long strategic review and will continue its operations on a stand-alone basis. The company also names a new CEO effective from May 20.
Strength Seen in Lifecore Biomedical (LFCR): Can Its 16.0% Jump Turn into More Strength?
by Zacks Equity Research
Lifecore Biomedical (LFCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Vanda Pharmaceuticals (VNDA) Reports Break-Even Earnings for Q3
by Zacks Equity Research
Vanda (VNDA) delivered earnings and revenue surprises of 100% and 12.78%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Will Lifecore Biomedical (LFCR) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Lifecore Biomedical (LFCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lifecore Biomedical (LFCR) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Lifecore Biomedical (LFCR) delivered earnings and revenue surprises of -1,171.43% and 8.80%, respectively, for the quarter ended May 2023. Do the numbers hold clues to what lies ahead for the stock?
LAVA Therapeutics N.V. (LVTX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
LAVA Therapeutics N.V. (LVTX) delivered earnings and revenue surprises of 0% and 105.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Immatics (IMTX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Immatics (IMTX) delivered earnings and revenue surprises of -2.94% and 28.28%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Emergent Biosolutions (EBS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -8.16% and 59.20%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Merus N.V. (MRUS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Merus N.V. (MRUS) delivered earnings and revenue surprises of 23.26% and 0.89%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Regeneron (REGN) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Regeneron (REGN) delivered earnings and revenue surprises of 3.23% and 4.77%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
QGEN vs. LFCR: Which Stock Is the Better Value Option?
by Zacks Equity Research
QGEN vs. LFCR: Which Stock Is the Better Value Option?
Evogene (EVGN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Evogene (EVGN) delivered earnings and revenue surprises of 6.25% and 26.32%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Senesco Technologies Inc. (ELOX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Senesco Technologies Inc. (ELOX) delivered earnings and revenue surprises of -12.94% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for May 15th
by Zacks Equity Research
ARGO, PFSI and LFCR have been added to the Zacks Rank #5 (Strong Sell) List on May 15, 2023.
Clene Inc. (CLNN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Clene Inc. (CLNN) delivered earnings and revenue surprises of 6.25% and 10.83%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Urogen Pharma (URGN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Urogen Pharma (URGN) delivered earnings and revenue surprises of 6.47% and 3.88%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for December 23rd
by Zacks Equity Research
SGRP, LFCR and MD have been added to the Zacks Rank #5 (Strong Sell) List on December 23, 2022.
Quipt Home Medical Corp. (QIPT) Beats Q4 Earnings Estimates
by Zacks Equity Research
Quipt Home Medical Corp. (QIPT) delivered earnings and revenue surprises of 25% and 1.01%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Avid Bioservices (CDMO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Avid Bioservices (CDMO) delivered earnings and revenue surprises of 0% and 12.12%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock?
Veru Inc. (VERU) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Veru Inc. (VERU) delivered earnings and revenue surprises of -75.86% and 77.51%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?